Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 230-256-0 | CAS number: 6990-06-3
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Link to relevant study record(s)
- Endpoint:
- basic toxicokinetics, other
- Remarks:
- Clinical overview
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- data from handbook or collection of data
- Objective of study:
- other: Pharmacokinetics
- Principles of method if other than guideline:
- Clinical studies on orally administrated fusidic acid in humans.
1. Single dose, 500 mg film-coated tablets, adults
2. Three times a day, 500 mg oral formulation, adults
3. Single dose, 20 mg/kg and 10 mg/kg, oral suspension, children - GLP compliance:
- no
- Specific details on test material used for the study:
- The clinical review covers sodium fusidate orally administrated in film-coated tablets, oral formulations and oral suspensions.
- Species:
- other: humans
- Sex:
- not specified
- Route of administration:
- oral: feed
- Vehicle:
- other: film-coated tablets, suspensions
- Details on exposure:
- 1. Single dose, 500 mg film-coated tablets, adults
2. Three times a day, 500 mg oral formulation, adults
3. Single dose, 20 mg/kg and 10 mg/kg, oral suspension, children - Details on absorption:
- 1. Single dose, 500 mg film-coated tablets, adults: 90-95% absorbed, serum concentration exceeding 10 mg/L after 1 hour and maximum levels reaching 30 mg/L at 3 hours. Elimination half life 9-16 hours.
2. Three times a day, 500 mg oral formulation, adults: mean accumulated serum concentration of 71 mg/L
3. Single dose, 20 mg/kg and 10 mg/kg, oral suspension, children: Maximum serum concentration of 16.9 mg/L after 2.7 hours (10 mg/kg). Elimination half life 16 h and 7.4 hours, respectively. - Details on distribution in tissues:
- Studies indicate that 90% of fusidic acid is reversibly bound to plasma proteins, fusidic acid distributes by diffusion into most tissues providing concentrations in various organs ranging from 20% to 90% of matching serum concentrations, and that 95% of a single dose is eliminated from serum over 24 hours via the bile.
- Test no.:
- #1
- Toxicokinetic parameters:
- half-life 1st: 9-16 hours
- Remarks:
- adults
- Test no.:
- #1
- Toxicokinetic parameters:
- C(time): 10 mg/L (1 hour)
- Test no.:
- #1
- Toxicokinetic parameters:
- Cmax: 30 mg/L (3 hours)
- Metabolites identified:
- not measured
- Bioaccessibility (or Bioavailability) testing results:
- 1. Bioavailability of fusidate in tablets in adults is approximately 91%.
3. Bioavailability of fusidic acid in oral suspension administrated to children is 22.5% (20 mg/L) and 30-40% (10 mg/L) - Conclusions:
- Approximately 90-95% of orally administrated sodium fusidate in a single dose is absorbed and maximum serum concentration levels are reached after approximately 3 hours. The studies indicate that 95% of a single dose is eliminated from serum over 24 hours via the bile.
- Executive summary:
In a clinical review on sodium fusidate orally administrated in film-coated tablets, oral formulations and oral suspensions, it is indicated that 90-95% of a single dose of sodium fusidate is absorbed and maximum serum concentration levels are reached after approximately 3 hours. Bioavailability is approximately 91% in adults and lower (22.5 -40%) in children.
The elimination half life of sodium fusidate/fusidic acid in serum is 9 -16 hours. The studies indicate that 95% of a single dose is eliminated from serum over 24 hours via the bile.
- Endpoint:
- dermal absorption in vivo
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- study well documented, meets generally accepted scientific principles, acceptable for assessment
- Principles of method if other than guideline:
- Study with eight male rabbits (New Zealand White). An area 6 cm x 10cm was shaved on the back of the rabbits. Four of the rabbits were treated with 1% sodium lauryl sulphate in vaseline. The remaining four rabbits were untreated. After 24 hours ca. 1g of salve was applied to the shaved area of all eight rabbits. Blood samples were taken after 0,2,4,6,8,24 and 48 hours after application.
- GLP compliance:
- no
- Specific details on test material used for the study:
- Salve containing 2% tritiated fucidin in fucidin salve (without lanolin) containing 0.68 mCi/g
- Radiolabelling:
- yes
- Species:
- rabbit
- Strain:
- New Zealand White
- Sex:
- male
- Details on test animals or test system and environmental conditions:
- Body weight between 2.55 and 3.05 kg.
- Type of coverage:
- open
- Vehicle:
- unchanged (no vehicle)
- Duration of exposure:
- 48 hours
- Doses:
- 1 g salve of 0.68 mCi/g
- No. of animals per group:
- 8
- Control animals:
- no
- Details on study design:
- An area 6 cm x 10cm was shaved on the back of the rabbits. Four of the rabbits were treated with 1% sodium lauryl sulphate in vaseline. The remaining four rabbits were untreated. After 24 hours ca. 1g of salve was applied to the shaved area of all 8 rabbits. Blood samples were taken after 0,2,4,6,8,24 and 48 hours after application. The animals were kept in stocks for the first 24 hours after application.
Serum was prepared from the blood samples. The serum samples were counted for up to 50 minines each in a Beckman CPM-100 liquid scintillation counter. Counting efficiency was determined from a previously prepared external standard quench correction curve. - Absorption in different matrices:
- Counts in serum from rabbits pretreated with lauryl sulphate were 3-45 times greater than in blank serum. In the untreated rabbits, many of the counts were less than twice blank.
Mean levels in the pretreated rabbits were roughly 10 times levels in the untreated animals. The highest single concentration obtained in any animal whilst in the stocks was 3.4 % dose/rabbit in pretreated animals, and 0.16% in intact animals. - Conclusions:
- The dermal absorption of sodium fusidate is very low, 0.02-0.16% based on results from a study in rabbits.
- Executive summary:
A dermal absorption study Study with eight male rabbits (New Zealand White) was performed. An area 6 cm x 10cm was shaved on the back of the rabbits. Four of the rabbits were treated with 1% sodium lauryl sulphate in vaseline. the remaining four rabbits were untreated. After 24 hours ca. 1g of salve was applied to the shaved area of all 8 rabbits. Blood samples were taken after 0,2,4,6,8,24 and 48 hours after application.
Serum levels in pretreated rabbits were 3-45 times greater than in blank serum. Levels in animals with intact skin were substantially lower.
The % dose absorbed was calculated assuming a distribution volume of 1 L/kg and was in pretreated rabbits 0.2-3.4% dose/rabbit and 0.02-0.16% in intact animals.
Referenceopen allclose all
The % dose absorbed was calculated assuming a distribution volume of 1 L/kg and was in pretreated rabbits 0.2-3.4% dose/rabbit and 0.02-0.16% in intact animals.
Mean % dose/rabbit at various time after dosing
Rabbit | 2 hours | 4 hours | 6 hours | 8 hours | 24 hours |
1 - pretreated | 0.547 | 0.702 | 3.357 | 0.790 | 1.824* |
2 - pretreated | 2.023 | 0.911 | 1.195 | 1.174 | 0.737 |
3 - pretreated | 0.300 | 0.965 | 0.356 | 0.322 | 0.200 |
4 - pretreated | 0.692 | 0.694 | 0.630 | 0.416 | 0.210 |
Mean - pretreated | 0.891 | 0.818 | 1.454 | 0.676 | 0.743 |
5 - unchanged skin | 0.033 | 0.116 | 0.088 | 0.101 | 2.284* |
6 - unchanged skin | 0.040 | 0.078 | 0.076 | 0.084 | 0.069 |
7 - unchanged skin | 0.045 | 0.047 | 0.114 | 0.065 | 0.155 |
8 - unchanged skin | 0.015 | Not valid | 0.028 | 0.020 | 0.073 |
Mean - unchanged skin | 0.033 | 0.080 | 0.077 | 0.068 | 0.0645 |
* Removed from stocks after 8 hours
Only blood samples obtained at times when the rabbit is confined in stocks are a valid expression of cutaneous absorption, since samples obtained later (48 hour) were in general higher and this is taken as evidence of oral absorption.
Counts in serum from rabbits pretreated with lauryl sulphate were 3-45 times greater than in blank serum. In the untreated rabbits, many of the counts were less than twice blank.
Mean levels in the pretreated rabbits were roughly 10 times levels in the untreated animals. The highest single concentration obtained in any animal whilst in the stocks was 3.4 % dose/rabbit in pretreated animals, and 0.16% in intact animals.
Description of key information
Human toxicokinetic data from oral administration available. In a clinical review on sodium fusidate orally administrated in film-coated tablets, oral formulations and oral suspensions, it is indicated that 90-95% of a single dose of sodium fusidate is absorbed and maximum serum concentration levels are reached after approximately 3 hours. Bioavailability is approximately 91% in adults and lower (22.5 -40%) in children.
The elimination half life of sodium fusidate/fusidic acid in serum is 9 -16 hours. The studies indicate that 95% of a single dose is eliminated from serum over 24 hours via the bile.
Absorption data from dermal study in rabbits available. A study with eight male rabbits (New Zealand White) was performed. Four of the rabbits were treated with 1% sodium lauryl sulphate in vaseline. the remaining four rabbits were untreated. After 24 hours ca. 1g of salve was applied to the shaved area of all 8 rabbits. Blood samples were taken after 0,2,4,6,8,24 and 48 hours after application.
Serum levels in pretreated rabbits were 3-45 times greater than in blank serum. Levels in animals with intact skin were substantially lower. The % dose absorbed was calculated assuming a distribution volume of 1 L/kg and was in pretreated rabbits 0.2-3.4% dose/rabbit and 0.02-0.16% in intact animals.
Available data from human and animal studies indicate high (95%) and very low (0.16%) absorption from oral and dermal administration, respectively with a low potential for bioaccumulation.
Key value for chemical safety assessment
- Bioaccumulation potential:
- low bioaccumulation potential
- Absorption rate - oral (%):
- 95
- Absorption rate - dermal (%):
- 0.16
- Absorption rate - inhalation (%):
- 0
Additional information
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.